Canaccord Genuity Sticks to Its Buy Rating for Stryker (SYK)

In a report released today, Caitlin Roberts from Canaccord Genuity maintained a Buy rating on Stryker, with a price target of $435.00.

Claim 30% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Roberts is an analyst with an average return of -2.0% and a 30.23% success rate. Roberts covers the Healthcare sector, focusing on stocks such as AxoGen, Vericel, and Establishment Labs Holdings.

In addition to Canaccord Genuity, Stryker also received a Buy from Citi’s Joanne Wuensch in a report issued on April 15. However, on April 13, Truist Financial maintained a Hold rating on Stryker (NYSE: SYK).

Based on Stryker’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.17 billion and a net profit of $849 million. In comparison, last year the company earned a revenue of $6.44 billion and had a net profit of $546 million

Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year. Most recently, in February 2026, Ronda Stryker, a Director at SYK sold 500,000.00 shares for a total of $181,717,233.87.